Dillon Cockrell, MD
@DCockrellMD
Followers
195
Following
139
Media
104
Statuses
246
Dad and husband | @DukeGUCancer GU Oncologist, DCI Center for Prostate and Urologic Cancers | Former @UNC Hem/Onc Chief Fellow | @vtcsom grad | Phase 1 trials
North Carolina
Joined June 2023
#CME Opportunity: Duke medical oncologist @DCockrellMD discusses risk factors and treatment options for high-risk prostate cancer and metastatic hormone-sensitive prostate cancer. 🔗 https://t.co/BI2eWihztf
@DukeCancer
0
1
1
I recently spoke at the @KidneyCancer Association Duke/UNC patient event on #RCC treatment. We covered: • Adjuvant pembro for higher-risk pts • IO/TKI and dual IO strategies • How we personalize treatment • Role of clinical trials 📽️ Full talk:
1
0
1
We had such an amazing patient education event at @UNC_Lineberger @DukeCancer last month! Still riding that high, knowing there are #kidneycancer communities ready to come together to learn and connect! Thanks to our faculty leads @Daniel_J_George and @catherine_fahey!
0
1
10
Interesting data from this paper in @JCO_ASCO. Starting to look like utDNA may offer similar insights for sensitive cancer detection in localized #bladdercancer as ctDNA has for advanced disease.
📣 Rapid Communication paper out in @JCO_ASCO | #SunRise4 primary findings & biomarkers ✅ pCR 38% w TAR200+Cet ✅ improved RFS w TAR200+Cet vs Cet mono ✅ 80% complete TURBT baseline revealed utDNA positivity ✅ utDNA status at w12 significantly associated with pCR ✅ utDNA
0
0
2
Great event yesterday! Enjoyed having the chance to talk with @KidneyCancer patients and caregivers about treatment options while also catching up with colleagues and mentors from @UNC_Lineberger and @DukeGUCancer. Thanks for leading @catherine_fahey @Daniel_J_George!
We are ready to welcome everyone to our #kidneycancer patient education event today together with @UNC_Lineberger @DukeCancer! 🧡💙
0
0
2
This is great news for our patients, HLD-0915 and the AR RIPTAC tech will continue development with a strong team @BGarmezy @AarmstrongDuke @charlesryanmd @DCockrellMD
Big Pharma movement following promising early phase 1/2 data from a trial led by our own @OncHahn @MDAndersonNews in men with progressing mCRPC. @PCFnews J&J buys into Halda's cell death tech with $3B acquisition, beefing up prostate cancer pipeline
0
5
30
Great news! Have been expecting earlier combinations with HIF2i’s to make their way into treatment soon. Particularly interested in seeing the adjuvant data and more effective post-IO options for advanced #RCC are sorely needed. @DrChoueiri
JUST IN: 2 Belzutifan (HIF2 inhibitor) phase III trials POSTIVE for Primary Endpoint in Renal Cell Carcinoma: LITEPSPAK022 (adjuvant) + LITESPARK011 (metastatic, post PD1). BIG NEWS for GU Oncology + Kidney Cancer patients! https://t.co/poOKpXP5nJ
https://t.co/wP9gu8ppLI
1
0
2
(6/6) Dose expansion at RDE starts soon at these sites across the US and UK. Encouraging start for RIPTACs in prostate cancer and beyond.
0
2
8
(5/6) Most exciting part is this novel MOA has very encouraging prelim activity against mCRPC. In pts with ≥ 6 wks tx, PSA50 was 59%, PSA90 was 32%, PR in 5/5 pts with RECIST-evaluable, and activity regardless prior tx or genomic alterations
2
7
17
(4/6) HLD-0915 is an oral, daily pill with minimal and manageable AEs across doses
1
2
4
(3/6) Here’s the phase 1 study design for men with mCRPC progressing on at least 1 ARPI. 31 pts dosed at data cut-off and study is ongoing
1
2
4
(2/6) What is a RIPTAC? The drug creates a stable ternary complex with a target protein (TP) and essential protein (EP) to inactivate the EP and cause cancer selective cell death. For HLD-0915, the TP is AR and EP is BRD4
1
2
6
Fortunate to be part of these efforts with HLD-0915, pushing the field forward for men with castration-resistant #prostatecancer. Phase 1 data w/ activity in a heavily pre-treated population. Great @AACR #Targets25 presentation, @OncHahn! @OncoAlert @oncodaily @DukeGUCancer
(1/6) Introducing an AR RIPTAC therapy, HLD-0915, for men with mCRPC by @HaldaTx We presented data from the FIH, phase 1 trial at the @AACR #Targets25 meeting. Here’s the Tweetorial for this active, tolerable, oral med and link to the slides https://t.co/mKbro4l0Or
0
0
3
(1/6) Introducing an AR RIPTAC therapy, HLD-0915, for men with mCRPC by @HaldaTx We presented data from the FIH, phase 1 trial at the @AACR #Targets25 meeting. Here’s the Tweetorial for this active, tolerable, oral med and link to the slides https://t.co/mKbro4l0Or
1
17
50
#CME Opportunity: Duke medical oncologist @DCockrellMD discusses risk factors and treatment options for high-risk prostate cancer and metastatic hormone-sensitive prostate cancer. Complete the CME ➡️ https://t.co/BI2eWihztf
@DukeCancer
1
1
0
It was a huge week for #BladderCancer at #ESMO25. Here are my takeaways from the most impactful trials pushing the field forward and improving patient care. 👇👇 @DukeGUCancer @GUOncologyNow @oncodaily @BladderCancerUS @Larvol @myESMO
1
9
25
Great to see the data for new SOC in cis-ineligible #MIBC with highest pCR yet. Big questions: - How to manage cis-eligible pts in light of #NIAGARA? - How many are over treated with adjuvant therapy or even surgery? - Whats the #ctDNA clearance - can we risk adapt? #ESMO25
@DrIacovelli @tompowles1 @OncoAlert @GUOncologyNow @Uromigos Impressive results from #KEYNOTE905 presented by Dr. Christof Vulsteke 👏 Full written coverage of perioperative EV + pembrolizumab in cisplatin-ineligible MIBC now live on @UroToday 👇 written by @chavarriagaj @myESMO @UroDocAsh 📝
0
0
0
#POTOMAC implementation would require a market shift in multidisciplinary care with med onc playing a larger role in treatment naive #NMIBC for systemic therapy, a disease mostly treated by community urologists. DFS can be a meaningful marker here but requires discussion. #ESMO25
Durvalumab in combination with BCG for BCG-naïve high-risk #NMIBC: Final analysis of the phase 3, open-label, randomized #POTOMAC trial. Presentation by @mdesantis234 @ChariteBerlin. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/s05aRUNwMi
@myESMO
0
1
6
ctDNA adapted treatment for adjuvant therapy in #bladdercancer is here, with the story being told across multiple trials. Time for us to move forward with sparing toxic therapy for patients who don’t need it. #ESMO25
Adjuvant nivo remains positive for DFS HR-0.73 but still not +ve for OS 0.83 in operable UC #ESMO25 . Enrichment occurred the ctDNA +ves (DFS HR=0.3 & OS HR=0.44) as in IMvigor010. The ctDNA negatives were at much lower risk didn’t seem to benefit from IO (HR-DFS 0.99, OS 0.87)
0
0
1
Looking forward to these studies hopefully sharing practice changing progress in #ProstateCancer at #ESMO25. Are we prepared for the coming flood of patients for RLTs in mHSPC? @oncodaily @GUOncologyNow @OncoAlert @myESMO @PCFnews @ZEROCancer @brunolarvol @UrologyTimes
GU Oncology Insights Ahead of ESMO 2025 - Dillon Cockrell (@DCockrellMD) https://t.co/d7WgOIW9R7
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #GUOnc #ESMO25 @CancerWorldmag
0
1
4